Exosome Therapy for Gum Disease: What a Pilot Clinical Study Found

Medically reviewed by Robin Baradarian, MD, board certified physician, and Alfred Shirzadnia, DDS, cosmetic and implant dentist.

Gum disease is one of the most common chronic conditions in adults, and it is far more than a cosmetic concern. Left unchecked, periodontitis can loosen teeth, destroy the bone that holds them in place and, eventually, lead to tooth loss. Standard treatments can stop the damage, but they rarely rebuild what has been lost. A 2024 pilot study published in the International Journal of Molecular Sciences is among the first to test exosome therapy for gum disease in human patients.^[1] Here is what the researchers did, what they found and what it means.

What Is Periodontitis?

Periodontitis is a chronic inflammatory disease that attacks the tissues supporting the teeth: the gums, the periodontal ligament and the jawbone. As it progresses, the gums pull away from the teeth and form “pockets” where bacteria collect, the attachment between tooth and gum is lost, and bone begins to break down.^[1,2]

Dentists classify periodontitis in four stages, from Stage I (initial, mild attachment loss) to Stage IV (severe, with extensive tooth loss).^[2] The condition is also linked with wider health issues, including cardiovascular disease and diabetes, which makes keeping inflammation under control especially important.^[3,4]

Why Conventional Treatment Has Limits

Treatment usually focuses on deep cleaning below the gumline (scaling and root planing), antimicrobial therapy and, in advanced cases, surgery.^[5] These approaches are effective at reducing bacteria and slowing the disease. However, they seldom restore the lost gum and bone structures. That gap is what has drawn researchers toward regenerative approaches.^[1,6]

What Are Extracellular Vesicles and Exosomes?

Extracellular vesicles (EVs) are tiny, membrane-wrapped particles that cells release to communicate with each other. They carry proteins, lipids and genetic material, and they can deliver signaling molecules that influence how immune cells respond and how tissue repairs itself.^[1,6]

Exosomes are the best-known type of EV. Following the latest international research guidelines (MISEV2023), the study authors use the broader term “EVs,” since a preparation typically contains several types of vesicles.^[1,7] In everyday conversation, you will often see the two terms used interchangeably.

Inflammation is at the heart of periodontitis. The body releases signaling proteins called cytokines in response to bacteria, and when that response becomes chronic, those same cytokines drive tissue breakdown and bone loss.^[8,9] Because EVs can help regulate immune signaling, researchers have proposed them as a way to calm this inflammation and support regeneration.^[6]

How the Study Worked

The study was carried out by researchers in Serbia and the United States and approved by the Ethics Committee of the Faculty of Dentistry at the University Business Academy in Novi Sad.^[1] It was designed as a proof-of-concept study, meaning its goal was to show whether EV therapy produces the expected biological response in patients.

• Participants: seven adults with generalized Stage I–III periodontitis (four men, three women, average age about 48) and seven healthy adults with no gum disease, who served as a reference for “normal” levels.
• Eligibility: participants were non-smokers, systemically healthy, had at least 20 natural teeth and had not recently received gum treatment, antibiotics or anti-inflammatory drugs.
• The treatment: EVs were isolated from blood plasma using a multi-step centrifugation process, then checked for size and concentration. Each patient received a single 0.8 mL dose containing roughly 6 billion EVs per mL.
• What was measured: a certified periodontologist recorded plaque, bleeding on probing, pocket (probing) depth and attachment level. Samples of the fluid around the gums were analyzed for 16 different cytokines. Measurements were taken before treatment and six weeks after.

What the Researchers Found

Healthier Gums in Six Weeks

All clinical measures improved significantly after a single treatment (p < 0.05).^[1]

Measure	Before treatment	Six weeks after
Average pocket depth	5.42 mm	4.14 mm
Average attachment level	6.20 mm	5.42 mm
Sites with plaque	100%	10%
Sites that bled on probing	100%	10%

Shallower pockets and a better attachment level suggest the gum tissue was reattaching more closely to the teeth. The sharp drop in bleeding points to much less active inflammation.

Inflammation Markers Fell to Healthy Levels

Before treatment, the active disease sites showed high levels of several inflammatory cytokines. Six weeks after treatment, eight of them had dropped significantly: IL-5, IL-6, IL-17A, IL-10, IL-21, TNF-α, IFN-γ and IL-12.^[1]

Perhaps the most striking finding was the comparison with the healthy group. Before treatment, patients’ cytokine profiles differed clearly from healthy individuals. Six weeks after treatment, none of the 16 cytokines showed a statistically significant difference between the two groups.^[1]

No Adverse Effects

No adverse effects were reported in any of the treated patients.^[1]

Why These Cytokines Matter

The cytokines that fell after treatment play central roles in how periodontitis damages tissue:

• IL-6 helps activate the cells that break down bone, contributing to bone loss when inflammation becomes chronic.^[10]
• IL-17A recruits inflammatory immune cells and promotes bone resorption.^[11]
• TNF-α is a powerful driver of inflammation that triggers other inflammatory signals and tissue destruction.^[12]

Lowering these signals may interrupt the cycle of inflammation and damage that keeps periodontitis progressing. The authors suggest this “calming” of the immune response may also create better conditions for tissue repair.^[1]

How EV Therapy Compares With Other Regenerative Options

Several regenerative approaches are already used or studied in gum care. Platelet-rich plasma (PRP) and platelet-rich fibrin (PRF), both made from a patient’s own blood, deliver growth factors that support healing and bone regeneration.^[13,14] Stem cell therapies, tissue-engineering scaffolds and growth factors such as bone morphogenetic proteins are also being explored.^[1]

According to the authors, EVs stand out because they occur naturally in the body, tend to be well tolerated and can deliver many signaling molecules at once. They are also “cell-free,” so no living cells are introduced.^[1,15]

Reading the Results With Perspective

These results are encouraging, but this was an early-stage study and the authors are clear about its limits:^[1]

• Very small sample: only seven patients received treatment.
• No placebo or standard-care group: the healthy participants were a reference point, not a control group, and the study was not randomized or blinded. A placebo effect cannot be ruled out.
• Short follow-up: six weeks shows early response, not long-term durability or whether repeat treatments are needed.
• Limited measures: no imaging or tissue analysis was done to confirm structural regeneration of bone or ligament.
• Preparation variability: methods for producing EVs are not yet standardized, which may affect consistency.

The authors also note that, as with any emerging therapy, the optimal dose, delivery method and long-term safety still need to be established in larger, randomized controlled trials.^[1]

Key Takeaways

• A single EV (exosome) treatment was followed by significant improvements in pocket depth, attachment level, plaque and bleeding after six weeks.
• Eight key inflammatory markers dropped significantly, and patients’ cytokine levels became statistically similar to those of healthy individuals.
• No adverse effects were reported.
• As a small proof-of-concept study without a placebo group, the findings are promising but need confirmation in larger, controlled trials.

This article summarizes published research for educational purposes and is not medical or dental advice. If you have symptoms of gum disease, such as bleeding, receding or swollen gums, please see your dentist or periodontist.

About the Medical Reviewers

Robin Baradarian, MD, board certified physician.

Alfred Shirzadnia, DDS, graduated from NYU College of Dentistry and completed an oral and maxillofacial surgery fellowship at Wyckoff Heights Medical Center, where he also served as chief surgical resident. His work focuses on cosmetic dentistry, dental implants and full mouth rehabilitation, and he is a member of the American Academy of Cosmetic Dentistry and the American Academy of Facial Esthetics.

References

1. Puletic M, Velikic G, Maric DM, Supic G, Maric DL, Radovic N, Avramov S, Vojvodic D. Clinical Efficacy of Extracellular Vesicle Therapy in Periodontitis: Reduced Inflammation and Enhanced Regeneration. Int J Mol Sci. 2024;25(11):5753. https://doi.org/10.3390/ijms25115753
2. Papapanou PN, Sanz M, Buduneli N, et al. Periodontitis: Consensus Report of Workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018;89(Suppl 1):S173–S182.
3. Febbraio M, Roy CB, Levin L. Is There a Causal Link between Periodontitis and Cardiovascular Disease? A Concise Review of Recent Findings. Int Dent J. 2022;72:37–51.
4. Zhao M, Xie Y, Gao W, Li C, Ye Q, Li Y. Diabetes Mellitus Promotes Susceptibility to Periodontitis—Novel Insight into the Molecular Mechanisms. Front Endocrinol. 2023;14:1192625.
5. Graziani F, Karapetsa D, Alonso B, Herrera D. Nonsurgical and Surgical Treatment of Periodontitis: How Many Options for One Disease? Periodontol 2000. 2017;75:152–188.
6. Lin H, Chen H, Zhao X, et al. Advances of Exosomes in Periodontitis Treatment. J Transl Med. 2022;20:279.
7. Welsh JA, Goberdhan DC, O’Driscoll L, et al. Minimal Information for Studies of Extracellular Vesicles (MISEV2023): From Basic to Advanced Approaches. J Extracell Vesicles. 2024;13:e12404.
8. Yang B, Pang X, Li Z, Chen Z, Wang Y. Immunomodulation in the Treatment of Periodontitis: Progress and Perspectives. Front Immunol. 2021;12:781378.
9. Stadler AF, Angst PD, Arce RM, et al. Gingival Crevicular Fluid Levels of Cytokines/Chemokines in Chronic Periodontitis: A Meta-Analysis. J Clin Periodontol. 2016;43:727–745.
10. Mazurek-Mochol M, Bonsmann T, Mochol M, Poniewierska-Baran A, Pawlik A. The Role of Interleukin 6 in Periodontitis and Its Complications. Int J Mol Sci. 2024;25:2146.
11. Feng Y, Chen Z, Tu SQ, et al. Role of Interleukin-17A in the Pathomechanisms of Periodontitis and Related Systemic Chronic Inflammatory Diseases. Front Immunol. 2022;13:862415.
12. Wang RPH, Huang J, Chan KWY, et al. IL-1β and TNF-α Play an Important Role in Modulating the Risk of Periodontitis and Alzheimer’s Disease. J Neuroinflammation. 2023;20:71.
13. Miron RJ, Zucchelli G, Pikos MA, et al. Use of Platelet-Rich Fibrin in Regenerative Dentistry: A Systematic Review. Clin Oral Investig. 2017;21:1913–1927.
14. Miron RJ, Fujioka-Kobayashi M, Sculean A, Zhang Y. Optimization of Platelet-Rich Fibrin. Periodontol 2000. 2023;94:79–91.
15. Koca-Ünsal RB, Chaurasia A. Roles of Exosomes in Regenerative Periodontology: A Narrative Review. Mol Biol Rep. 2022;49:12219–12225.